Get started
Author

Koby Mok

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
2022 · Lawrence Steinman, Edward Fox, et al. · New England Journal of Medicine · 250
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
2020 · Edward Fox, Amy E Lovett-Racke, et al. · Multiple Sclerosis Journal · 128
PDF
Gonadal steroid regulation of renal injury in renal wrap hypertension
2004 · Hong Ji, Stefano Menini, et al. · American Journal of Physiology-Renal Physiology · 67
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis
2024 · Enrique Alvarez, Lawrence Steinman, et al. · Frontiers in Neurology · 12
PDF
Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study
2026 · Bruce A. C. Cree, Edward Fox, et al. · JAMA Neurology · 10
Efficacy and safety of ublituximab versus teriflunomide in relapsing multiple sclerosis: Results of the Phase 3 ULTIMATE I and II trials (4494)
2021 · Lawrence Steinman, Edward Fox, et al. · Neurology · 5
Ublituximab Efficacy in Treatment-Naive Participants With Relapsing Multiple Sclerosis in the Phase 3 ULTIMATE I and II Studies (P6-3.015)
2023 · Lawrence Steinman, Edward Fox, et al. · Neurology · 4
Disease Outcomes With Ublituximab in Participants With Highly Active Disease: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis (P6-3.002)
2023 · Enrique Alvarez, Lawrence Steinman, et al. · Neurology · 3
Infusion-Related Reactions (IRRs) With Ublituximab in Patients With Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses From the Phase 3 ULTIMATE I and II Studies (P6-4.010)
2022 · Edward Fox, Lawrence Steinman, et al. · Neurology · 3
Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations From the Phase 3 ULTIMATE I and II Studies (P5-4.009)
2022 · Bruce Cree, Edward Fox, et al. · Neurology · 2
Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis
2026 · Derrick Robertson, Enrique Alvarez, et al. · Frontiers in Immunology · 1
PDF
Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies (P9-6.017)
2024 · Derrick Robertson, Hans-Peter Hartung, et al. · Neurology · 1
Relapse Rate and Time to First Relapse Were Improved With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients With Relapsing Multiple Sclerosis (RMS) (P1-1.Virtual)
2022 · Lawrence Steinman, Edward Fox, et al. · Neurology · 1
Open Label Extension (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS) (P3.2-048)
2019 · Edward Fox, Sibyl Wray, et al. · Neurology · 1
Final MRI Results At 6 Months From A Phase 2 Multicenter Study Of Ublituximab, A Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), In Patients With Relapsing Forms Of Multiple Sclerosis (RMS), Demonstrates Complete Elimination Of Gd-Enhancing Lesions (P3.409)
2018 · Matilde Inglese, Maria Petracca, et al. · Neurology · 1
Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis
2026 · Hans-Peter Hartung, Derrick Robertson, et al. · Neurology and Therapy
PDF
Five Years of Ublituximab in Relapsing Multiple Sclerosis: Additional Results from Open-label Extension of ULTIMATE I and II Studies (P11-1.006)
2025 · Bruce Cree, Edward Fox, et al. · Neurology
No Association Between Decreases in Serum Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) and Serious Infections (SI) with Long-term Ublituximab (UBL) Treatment in Patients with Relapsing Multiple Sclerosis (RMS) (P7-1.017)
2025 · Lawrence Steinman, Edward Fox, et al. · Neurology
Earlier Initiation of Ublituximab Treatment Is Associated with Improved Disability Outcomes Among Treatment Naïve Participants in ULTIMATE I and II (P9-6.001)
2024 · Derrick Robertson, Hans-Peter Hartung, et al. · Neurology
Ublituximab Treatment Is Associated With a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results From the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS) (P6-4.005)
2022 · Enrique Alvarez, Lawrence Steinman, et al. · Neurology
Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 mAb, in Patients with RMS (1167)
2020 · Edward Fox, Sibyl Wray, et al. · Neurology
Baseline Demographics and Disease Characteristics from the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis (4845)
2020 · Lawrence Steinman, Edward Fox, et al. · Neurology
Analysis of Cytosolic Proteins that Bind to the 5' Leader Sequence of the Angiotensin AT1 Receptor by RNA Electromobility Shift Assay
2003 · Zheng Wu, Kamakshi Krishnamurthi, et al. · Humana Press eBooks
Works count: 23
Citation count: 489
H-index: 5
I10-index: 5
Year
Topic
Type